Considerations for talking to your patients about using bypassing agents while they are on HEMLIBRA® prophylaxis

Educate patients and caregivers to think differently about treating breakthrough bleeds
  • Discuss the signs and symptoms of bleeds that require bypassing agents and when to seek medical advice before treating these bleeds
  • Explain that HEMLIBRA increases the potential for blood to clot, so it’s important to discuss the use of bypassing agents prior to starting HEMLIBRA prophylaxis
  • Describe the potential risks of TMA and thromboembolism if aPCC is administered while taking HEMLIBRA
  • Encourage patients to update emergency medical information and to advise any healthcare provider about potential risks with concomitant aPCC
Make a plan with your patients and caregivers for how to appropriately use bypassing agents when using HEMLIBRA
  • Consider the benefits and risks if aPCC must be used in a patient taking HEMLIBRA
  • Ensure patients and caregivers know to consult their healthcare provider if aPCC is required in cumulative doses exceeding 100 U/kg
Monitor for TMA and thromboembolism if administering aPCC
  • Discuss the signs and symptoms of TMA and thromboembolism
  • Ensure patients and caregivers know to contact their healthcare provider and seek immediate medical treatment if they suspect signs or symtpoms of TMA or thromboembolism
  • Immediately discontinue aPCC and suspend dosing of HEMLIBRA if clinical symptoms, imaging, or laboratory findings consistent with these events occur, and manage as clinically indicated
  • Consider the benefits and risks of resuming HEMLIBRA prophylaxis following complete resolution of these events on a case-by-case basis

Treating Breakthrough Bleeds

Guidelines for addressing breakthrough bleeds


Stay up-to-date with informative webcast events

HEMLIBRA Laboratory Monitoring Information

Considerations for using laboratory tests to monitor patients taking HEMLIBRA